Anlotinib is an oral multi-targeted tyrosine kinase inhibitor, primarily indicated for the targeted therapy of specific advanced cancers. To balance therapeutic efficacy and safety, it is imperative to strictly follow the doctor's instructions during administration, with special attention to administration timing, dose adjustment, adverse reaction monitoring, and contraindications.
Indications and Administration Specifications
Anlotinib is indicated for patients with advanced non-small cell lung cancer (NSCLC), soft tissue sarcoma, and other specified cancers who have previously received at least two lines of systemic chemotherapy. Its use must be evaluated by a specialist physician, and the treatment regimen shall not be adjusted without medical guidance.
The medication should be taken on an empty stomach (2 hours before or after meals) at a fixed time daily to avoid missed doses. If a dose is missed and less than 12 hours remain until the next scheduled dose, the missed dose should be skipped.
Dose Adjustment and Adverse Reaction Management
Based on the severity of adverse reactions (e.g., hemorrhage, hypertension), physicians may adjust the dosage or temporarily discontinue treatment. Common side effects include hypertension, hand-foot skin reaction, fatigue, and diarrhea. Regular monitoring of blood pressure and blood routine is required.
Immediate drug withdrawal and medical attention are mandatory in cases of severe hemorrhage (e.g., hemoptysis, melena) or allergic reactions (e.g., skin rash, dyspnea).
Contraindications and High-Risk Populations
Anlotinib is contraindicated in the following populations:
1.Patients with central squamous cell lung cancer;
2.Patients with active bleeding or high bleeding risk;
3.Patients with moderate to severe hepatic or renal insufficiency;
Pregnant women, lactating women, and women planning pregnancy. Strict contraceptive measures must be adopted during the treatment period.
Drug Interactions and Special Populations
Avoid concurrent use with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), and potent CYP3A4 inhibitors (e.g., ketoconazole), as such combinations may increase the risk of bleeding or metabolic abnormalities.
Elderly patients should use the drug with caution, and a reduced initial dose may be required. Close monitoring is necessary for patients with hepatic or renal insufficiency.
Storage and Follow-up
Storage conditions: Preserve in a light-protected place below 25°C, and keep out of the reach of children to prevent accidental ingestion.
Follow-up requirements: During treatment, recheck blood routine, liver and kidney functions, and conduct imaging examinations to evaluate therapeutic efficacy every 2–4 weeks. Patients on long-term therapy should undergo regular electrocardiogram (ECG) and thyroid function monitoring.
Important Note: Anlotinib is a prescription-only medication and must be used under the supervision of an oncology specialist. Any abnormal symptoms occurring during treatment should be promptly reported to the physician for regimen adjustment.
